{"id":"W2752688736","doi":"10.1111/jdv.14581","title":"Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase <scp>III</scp> trials","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Guenther Dermatology Research Centre; Western University","funders":"Eli Lilly and Company","keywords":"Psoriasis; Ixekizumab; Medicine; Placebo; Psoriasis Area and Severity Index; Dermatology; Dermatology Life Quality Index; Quality of life (healthcare); Internal medicine; Secukinumab; Pathology; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00921788,0.001259136,0.003717869,0.0004410853,0.0003519655,0.001254214,0.0007293497,0.001383167,0.001734598],"category_scores_gemma":[0.004731671,0.0005235518,0.005801679,0.0006716509,0.0006069177,0.0005627635,0.0004534372,0.002021204,0.0002397042],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006572943,"about_ca_system_score_gemma":0.0008138554,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006708599,"about_ca_topic_score_gemma":0.00157158,"domain_scores_codex":[0.9967526,0.002018176,0.000356762,0.0002868891,0.0003953113,0.0001903648],"domain_scores_gemma":[0.9956209,0.001658885,0.001620801,0.0002591241,0.0003128243,0.0005274725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8656328,0.006403618,0.02076171,0.004212571,0.02240483,0.00007363398,0.0001417121,0.001182325,0.004510592,0.00007149112,0.002005252,0.07259937],"study_design_scores_gemma":[0.7786178,0.1126093,0.09326191,0.0004407566,0.01095199,0.0002540612,0.00005921592,0.0009170561,0.001135122,0.0001301377,0.001565349,0.00005727768],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9563702,0.03770347,0.0006192023,0.0006229981,0.0001597303,0.001442351,0.001598925,0.00007102341,0.001412137],"genre_scores_gemma":[0.9838007,0.009756555,0.001155827,0.0006007704,0.0002583078,0.001761115,0.002036291,0.00001848041,0.0006119828],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00921788,"threshold_uncertainty_score":0.04874933,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07829322909685908,"score_gpt":0.3374125181614959,"score_spread":0.2591192890646368,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}